Key Players
Competitive Landscape
A company’s position depends on the medicines for which it can sustain access, rather than on a single ranking across all biological products. Pfizer Inc. and Amgen Inc. participate in both biological treatment development and biosimilar competition, while Hoffmann-La Roche AG and AbbVie Inc. bring established biological-medicine portfolios and Biocon Limited contributes biosimilar capabilities. Competitive pressure consequently differs between molecules and treatment settings, with the comparative evidence tied to the particular reference medicine. FDA and EMA requirements establish the scientific basis for an authorized biosimilar, while national purchasing and substitution arrangements influence subsequent uptake. Manufacturing continuity and support for treatment delivery remain practical differentiators as purchasers consider the available product options. [1][2][3]
Regulatory and industry developments mapped to drivers, trends and opportunities (2026 to 2036)
Table 10: Regulatory and industry developments in Biosimilar and Biologics Market
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| The MHRA updated its biosimilar licensing guidance in February 2025. [4] | Developers need a product-specific evidence package for the applicable licensing route. | Reference-product selection and comparability remain central to biosimilar development. | A prepared UK program can connect manufacturing readiness with the evidence needed for the intended product. |
| WHO's 2022 evaluation guidelines set out principles for licensing biosimilars. [3] | Demonstrated similarity underpins the regulatory assessment of a biosimilar. | Product comparison is organized around the particular reference biological medicine. | Developers can align manufacturing and comparative-evidence work before commercial supply is established. |
| EMA distinguishes scientific interchangeability assessment from pharmacy-substitution decisions made by individual member states. [2] | Authorization and treatment-channel adoption involve different health-system decisions. | Commercial uptake varies with local prescribing and purchasing arrangements. | Suppliers can prepare product information and channel support around the access conditions of each market. |
Source: European Medicines Agency; World Health Organization; UK Medicines and Healthcare products Regulatory Agency.
How do reference-product and biosimilar companies compete?
Competition takes place around individual medicines and treatment settings, with some companies active in both reference biologics and biosimilars. Pfizer Inc. and Amgen Inc. participate across those roles, while Hoffmann-La Roche AG and AbbVie Inc. bring established biological-treatment portfolios and Biocon Limited contributes biosimilar development capabilities. For purchasers, the available options depend on the particular reference medicine and authorized alternatives, with comparative evidence and local treatment arrangements shaping the commercial contest. [1][2]
Which capabilities support an enduring supplier position?
A biological medicine needs consistent production as well as a development package appropriate to its regulatory route, making manufacturing and product evidence closely connected. WHO's biosimilar guidelines and MHRA licensing guidance address the relationship between similarity, quality documentation and assessment. [3][4] Suppliers with reference products or biosimilar programs consequently compete through the medicines they can make available for a specific therapeutic use, with dependable supply allowing an authorized option to fit routine treatment rather than remain a procurement possibility.
What should purchasers compare before choosing a biological-medicine supplier?
The medicine and intended treatment setting establish the starting point, followed by the authorization status, relevant comparative evidence and availability of supply. Local prescribing and purchasing rules then affect how an option reaches patients, particularly where pharmacy substitution is determined nationally. [1][2] A useful supplier assessment therefore connects the product with its delivery channel and manufacturing continuity, giving the purchaser a practical view of whether the proposed supply arrangement can support the treatment pathway over time. [3]
How might competition evolve through 2036?
Eligible reference medicines losing exclusivity can create further biosimilar opportunities, but the strength of competition will differ between molecules as development requirements and treatment channels vary. Suppliers will need to combine the evidence for similarity with reliable manufacturing and access arrangements that work in the health system being served. [1][2][3] Portfolio breadth can offer several routes to participation, while each individual product still needs to establish its place in the purchasing and prescribing conditions that govern actual uptake.
Representative Company Overview
Table 11: Representative company overview for biosimilar and biologics market
| Company | Positioning | Recent development or documented offering |
|---|---|---|
| Pfizer Inc. | Reference biologic and biosimilar portfolios | Its participation across biological treatments and biosimilars gives purchasers product-specific options from both parts of the field, with the relevant comparison tied to the molecule and treatment setting. |
| Hoffmann-La Roche AG | Biological medicines | Its biological-treatment portfolios serve major therapeutic areas, making continuity of the relevant medicine and its fit within the treatment pathway central to the supply relationship. |
| AbbVie Inc. | Immunology and other biological treatments | Its established biological-medicine franchises place product access and continuity at the center of purchasing discussions, particularly where ongoing treatment requires dependable availability. |
| Amgen Inc. | Biotechnology medicines and biosimilars | Its biological development and biosimilar activities provide different routes to competition, requiring purchasers to assess the specific authorized product and supply proposition for the intended therapeutic use. |
| Biocon Limited | Biological and biosimilar development | Its biosimilar capabilities address additional biological-treatment options, with comparative evidence, manufacturing readiness and the route into routine prescribing determining the practical access proposition. |
Research Methodology
Research covers reference biological medicines and biosimilars within one biological-medicine revenue boundary, excluding conventional small-molecule chemical drugs. FDA and EMA explanations establish the distinction between similarity, interchangeability and authorization, while WHO guidance informs the assessment of comparative development and product quality. [1][2][3] Drug class and application are considered separately from manufacturing, source and distribution, because a treatment’s clinical role does not identify its production platform or route to the patient. MHRA guidance adds a UK licensing reference for biosimilar programs. [4] Geographic assessment follows prescribing, procurement and treatment access within the broad market, and competitive comparison examines actual portfolios and supply capabilities at individual-product level. Historical values and forecasts retain consistent units, with biosimilars included within the biological-medicine total.
